Drug and Therapeutics Bulletin 2005;43:41-45; doi:10.1136/dtb.2005.43641
Copyright © 2005 by the BMJ Publishing Group Ltd.

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

Hypertension in type 2 diabetes - targeting angiotensin

Relevant BNF section: 2.5.5

Cardiovascular disease accounts for around 60% of deaths in people with type 2 diabetes mellitus, and diabetes is the leading cause of renal dysfunction and premature death in the UK.^1,2 A key factor in these outcomes is that many people with type 2 diabetes also have raised blood pressure, which increases the likelihood of vascular complications.^3–5 Lowering elevated blood pressure, using one or more antihypertensive drugs, reduces illness and mortality rates in such people.^6,7 National guidelines advocate the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-II receptor antagonists in selected patients with type 2 diabetes.^3,8,9 Here we review whether such treatment offers advantages over other antihypertensive drugs.